Tetra Partners With Cellvera To Develop An Oral Treatment For COVID-19
Tetra Partners With Cellvera To Develop An Oral Treatment For COVID-19
Tetra Bio-Pharma Inc. (OTCQB:TBPMF) (TSX:TBP) (FRA: JAM1), signed an agreement with Cellvera Global Holdings LLC, for the co-development of ARDS-003 as a combination product, with Qifenda 400mg (Favipiravir), a commercial-stage broad-spectrum antiviral drug.
利乐生物制药公司。(场外交易代码：TBPMF)(多伦多证券交易所股票代码：TBP)(法兰克福证券交易所股票代码：JAM1)，与Cellvera Global Holdings LLC，适用于共同开发ARDS-003作为组合产品，与奇芬达400毫克(法维拉韦)，一个商业舞台广谱抗病毒药物.
As a monotherapy, compared to placebo, ARDS-003 dose-dependently reduced signs of morbidity and mortality, including respiratory distress following SARS-CoV-2 infection in the humanized ACE2 mouse model. ARDS-003 also outperformed an antiviral drug in reducing multiple proinflammatory mediators involved in hyperinflammation and immune system dysfunction following viral infection. Other studies have also demonstrated dose-dependent inhibition of viral replication.
作为一种单一疗法，与安慰剂相比，ARDS-003剂量依赖地减少了发病率和死亡率的迹象，包括人源化ACE2小鼠模型中SARS-CoV-2感染后的呼吸窘迫。ARDS-003在减少参与病毒感染后的过度炎症和免疫系统功能障碍的多种促炎介质方面也优于一种抗病毒药物。其他研究也证明了对病毒复制的剂量依赖性抑制。
Cellvera owns the rights to the brand originator Favipiravir, initially developed by FujiFilm Toyama Chemical Co and approved in Japan to treat pandemic influenza. Favipiravir is a selective inhibitor of viral RNA-dependent RNA polymerase with potent antiviral activity against single-stranded RNA viruses, including coronaviruses. It targets the protein needed for the coronavirus to replicate, making it impossible for the virus to copy itself. According to the company, the broad-spectrum antiviral drug is effective against 12 families of viruses, including Coronaviruses (COVID, MERS, SARS), Filoviruses (EBOLA, MARBURG), Flaviviruses (ZIKA, WEST NILE, DENGUE), RABIES, NOROVIRUS, and many others.
Cellvera拥有品牌发起人Favipiravir的权利，Favipiravir最初由富士富山化学公司并在日本被批准用于治疗大流行性流感。法韦拉韦是一种选择性的病毒RNA依赖的RNA聚合酶抑制剂，对包括冠状病毒在内的单链RNA病毒具有很强的抗病毒活性。它针对冠状病毒复制所需的蛋白质，使病毒不可能复制自己。据该公司称，这种广谱抗病毒药物对12个病毒家族有效，包括冠状病毒(COVID、MERS、SARS)、丝状病毒(埃博拉、马尔堡)、黄病毒(寨卡病毒、西尼罗河病毒、登革热)、狂犬病、诺沃克病毒等。
As novel strains of the SARS-CoV-2 virus continue to emerge, preliminary studies on SARS-COV-2 Variants, Omicron and Delta, have shown that Favipiravir maintains its antiviral activity, demonstrating viruses' inability to resist Favipiravir even with prolonged exposure of virus-infected cells to the drug. Clinical trials of Favipiravir have shown rapid viral clearance and prevention of hospitalization when administered early in the onset of the symptoms.
随着新的SARS-CoV-2病毒株的不断出现，对SARS-CoV-2变种奥密克戎和Delta的初步研究表明，法比拉韦保持了其抗病毒活性，表明即使病毒感染细胞长期接触这种药物，病毒也无法抵抗法维拉韦。Favipiravir的临床试验表明，如果在症状出现的早期使用，病毒迅速清除并防止住院。
The parties hypothesize, based on data from AI based in-silico drug discovery platform Prepaire, that a combination product of Favipiravir and ARDS-003 has the potential to allow rapid virus clearance and provide longer-term patient benefits. ARDS-003's cytokine reduction properties may prevent some consequences of SARS-CoV-2 infection, such as severe pulmonary inflammation.
各方假设，基于基于人工智能的数据硅内药物发现平台 做好准备Favipiravir和ARDS-003的组合产品有可能实现病毒的快速清除，并为患者提供更长期的好处。ARDS-003的细胞因子减少特性可能预防SARS-CoV-2感染的一些后果，如严重的肺部炎症。
Mary O'Brien, CEO of Cellvera, stated: "The ongoing complexities of COVID-19 require multiple treatment options. By joining forces with Tetra, we hope to offer this additional treatment option to patients. This collaboration with Tetra supports our partnership strategy and the development of further combination therapies involving Qifenda. We share a passion with Tetra to deliver innovative medicines to address this pandemic. We look forward to working with Guy and his team to investigate the potential of ARDS-003 and Qfienda. By joining the Prepaire partner platform, we connect with like-minded experts from across industry, academia, and the government sector, we are better equipped to lead the way towards transforming drug discovery and development through the application of machine learning".
玛丽·奥布莱恩Cellvera首席执行官刘强东表示：“新冠肺炎目前的复杂性要求有多种治疗方案。通过与利乐的合作，我们希望为患者提供这种额外的治疗选择。与利乐的合作支持了我们的伙伴关系战略和涉及奇芬达的进一步联合疗法的开发。我们与利乐有着共同的热情，即提供创新的药物来应对这一流行病。我们期待着与盖伊和他的团队合作，调查ARDS-003和Qfienda的潜力。通过加入Prepreire合作伙伴平台，我们与来自工业界、学术界和政府部门的志同道合的专家建立了联系，我们更有能力通过应用机器学习来引领药物发现和开发的变革。
Photo: Benzinga; Sources: courtesy of geralt, lindsayfox via Pixabay
图片来源：Geralt，lindsayfox通过pixabay提供
Related News
相关新闻
Preclinical Trial Results Confirm Targeting Type 2 Cannabinoid Receptors Helps Relieve Sepsis-Related Condition
临床前试验结果证实靶向2型大麻素受体有助于缓解脓毒症相关疾病
Akanda To Supply Tetra Bio-Pharma With Cannabis For FDA Trials Of Cancer-Pain Drug
阿坎达将向利乐生物制药公司提供大麻，用于FDA的癌症止痛药试验
Tetra Bio-Pharma Opens New Subsidiary In Australia And Provides Regulatory Update
利乐生物制药公司在澳大利亚开设新子公司并提供最新监管信息
译文内容由第三方软件翻译。